Thera-SAbDab

MONALIZUMAB

>   Structural Summary
TherapeuticMonalizumab
TargetKLRC1
Heavy ChainQVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMNWVRQAPGQGLEWMGRIDPYDSETHYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARGGYDFDVGTLYWFFDVWGQGTTVTVSS
Light ChainDIQMTQSPSSLSASVGDRVTITCRASENIYSYLAWYQQKPGKAPKLLIYNAKTLAEGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHHYGTPRTFGGGTKVEIK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG4
Highest Clinical Trial (June '19)Phase-II
Estimated Status (June '19)Active
Recorded Developmental Technologyna
INN Year Proposed2015
INN Year Recommended2016
Companies InvolvedInnate Pharma, MedImmune, NCIC Clinical Trials Group, Novo Nordisk
Conditions Approvedna
Conditions ActiveHead and neck cancer, Non-small cell lung cancer, Cervical cancer, Chronic lymphocytic leukaemia, Endometrial cancer, Fallopian tube cancer, Ovarian cancer, Peritoneal cancer, Solid tumours, Haematological malignancies
Conditions DiscontinuedInflammation, Rheumatoid arthritis
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]